Determination of thalidomide concentration in human plasma by liquid chromatography-tandem mass spectrometry

Nan Bai, Xiang-Yong Cui, Jin Wang, Chun-Guang Sun, He-Kun Mei, Bei-Bei Liang, Yun Cai, Xiu-Jie Song, Jing-Kai Gu, Rui Wang, Nan Bai, Xiang-Yong Cui, Jin Wang, Chun-Guang Sun, He-Kun Mei, Bei-Bei Liang, Yun Cai, Xiu-Jie Song, Jing-Kai Gu, Rui Wang

Abstract

A rapid, sensitive and specific analytical method based on high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) has been developed for the determination of thalidomide concentration in human plasma. The analyte and internal standard were extracted by liquid-liquid extraction with ether-dichloromethane (3:2, v/v) and separated on a TC-C(18) column using methanol-10 mM ammonium acetate-formic acid (60:40:0.04, v/v/v) as the mobile phase at a flow rate of 0.9 ml/min. The detection was performed using an API 4000 triple quadrupole mass spectrometer in the positive electrospray ionization (ESI) mode and completed within 3.0 min. The multiple reaction monitoring (MRM) transitions were m/z 259.1→84.0 for the analyte and m/z 195.9→138.9 for temozolomide. The calibration curve exhibited a linear dynamic range of 2-1500 ng/ml (r>0.9991). The intra-and inter-day precisions (as relative standard deviation; RSD) were 6.8-13.5% and 4.3-5.0% respectively and the accuracy (as relative error; RE) was 2.0-3.5%. The recoveries and matrix effects were satisfactory in all the biological matrices examined. This method was successfully used in a pharmacokinetic study of thalidomide in healthy male volunteers receiving an oral administration of a 200-mg dose.

Keywords: human plasma; liquid chromatography-tandem mass spectrometry; multiple reaction monitoring; thalidomide.

Figures

Figure 1.
Figure 1.
Full-scan product ion spectra of [M+H]+ for (A) thalidomide and (B) temozolomide.
Figure 2.
Figure 2.
Representative MRM chromatograms of thalidomide in plasma. (A) Blank plasma; (B) blank plasma spiked with thalidomide (2 ng/ml) or internal standard (100 ng/ml); (C) plasma sample 1 h after the oral administration of a 200-mg dose. I, thalidomide; II, temozolomide; MRM, multiple reaction monitoring.
Figure 3.
Figure 3.
Mean plasma concentration-time profile for 200 mg thalidomide.

References

    1. Calabrese L, Resztak K. Thalidomide revisited: pharmacology and clinical applications. Expert Opin Investig Drugs. 1998;7:2043–2060.
    1. Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 2004;3:47–56.
    1. Kamikawa R, Ikawa K, Morikawa N, Asaoku H, Iwato K, Sasaki A. The pharmacokinetics of low-dose thalidomide in Japanese patients with refractory multiple myeloma. Biol Pharm Bull. 2006;29:2331–2334.
    1. Yakoub-Agha I, Attal M, Dumontet C, et al. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients - report of the Intergroupe Francophone du Myélome (IFM) Hematol J. 2002;3:185–192.
    1. Barillé-Nion S, Barlogie B, Bataille R, et al. Advances in biology and therapy of multiple myeloma. Hematology. Am Soc Hematol Educ Program. 2003:248–278.
    1. Lehman TJ, Schechter SJ, Sundel RP, Oliveira SK, Huttenlocher A, Onel KB. Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study. J Pediatr. 2004;145:856–857.
    1. Heine RG, Cameron DJ, Chow CW, Hill DJ, Catto-Smith AG. Esophagitis in distressed infants: poor diagnostic agreement between esophageal pH monitoring and histopathologic findings. J Pediatr. 2002;140:14–19.
    1. Akkoc N, van der Linden S, Khan MA. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy. Best Pract Res Clin Rheumatol. 2006;20:539–557.
    1. van der Horst-Bruinsma IE, Clegg DO, Dijkmans BA. Treatment of ankylosing spondylitis with disease modifying antirheumatic drugs. Clin Exp Rheumatol. 2002;20(6 Suppl 28):S67–S70.
    1. Zlnay D, Zlnay M, Rovenský J. Ankylosing spondylitis - the current situation and new therapeutic options. Vnitr Lek. 2006;52:730–735. (In Slovak).
    1. Mansfield JC, Parkes M, Hawthorne AB, et al. A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn’s disease. Aliment Pharmacol Ther. 2007;26:421–430.
    1. Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech. 2000;50:229–235.
    1. Brocard A, Barbarot S, Milpied B, Stalder JF. Thalidomide in the treatment of chronic discoid lupus erythematosus. Ann Dermatol Venereol. 2005;132:853–856. (In French).
    1. Bang D. Treatment of Behçet’s disease. Yonsei Med J. 1997;38:401–410.
    1. Chung F, Lu J, Palmer BD, et al. Thalidomide pharmacokinetics and metabolite formation in mice, rabbits, and multiple myeloma patients. Clin Cancer Res. 2004;10:5949–5956.
    1. Eriksson T, Björkman S, Fyge A, Ekberg H. Determination of thalidomide in plasma and blood by high-performance liquid chromatography: avoiding hydrolytic degradation. J Chromatogr. 1992;582:211–216.
    1. Huang YJ, Liao JF, Tsai TH. Concurrent determination of thalidomide in rat blood, brain and bile using multiple microdialysis coupled to liquid chromatography. Biomed Chromatogr. 2005;19:488–493.
    1. Teo SK, Colburn WA, Thomas SD. Single-dose oral pharmacokinetics of three formulations of thalidomide in healthy male volunteers. J Clin Pharmacol. 1999;39:1162–1168.
    1. Saccomanni G, Turini V, Manera C, et al. High performance liquid chromatographic determination of thalidomide in patients affected by hepatocellular carcinoma. J Pharm Biomed Anal. 2008;48:447–451.
    1. Yang X, Hu Z, Chan SY, et al. Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat. J Pharm Biomed Anal. 2005;39:299–304.
    1. Chen TL, Vogelsang GB, Petty BG, et al. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers. Drug Metab Dispos. 1989;17:402–405.
    1. Zhou S, Li Y, Kestell P, Paxton JW. Determination of thalidomide in transport buffer for Caco-2 cell monolayers by high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2003;785:165–173.
    1. Toraño JS, Verbon A, Guchelaar HJ. Quantitative determination of thalidomide in human serum with high-performance liquid chromatography using protein precipitation with trichloroacetic acid and ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1999;734:203–210.
    1. Teo SK, Chandula RS, Harden JL, Stirling DI, Thomas SD. Sensitive and rapid method for the determination of thalidomide in human plasma and semen using solid-phase extraction and liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;767:145–151.
    1. Teo SK, Harden JL, Burke AB, et al. Thalidomide is distributed into human semen after oral dosing. Drug Metab Dispos. 2001;29:1355–1357.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다